ANDROGENETIC ALOPECIA (AGA)
Clinical trials for ANDROGENETIC ALOPECIA (AGA) explained in plain language.
Never miss a new study
Get alerted when new ANDROGENETIC ALOPECIA (AGA) trials appear
Sign up with your email to follow new studies for ANDROGENETIC ALOPECIA (AGA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hair loss drug shows promise in early trial
Disease control CompletedThis study tested a new drug called CG2001 for male pattern baldness in 110 Chinese men aged 18 to 65. The main goal was to see if it increases hair count after 24 weeks and to find the best dose for future studies. The trial also checked for side effects.
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: PHASE2 • Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 09:05 UTC
-
Hair loss supplement put to the test in 240-Person trial
Disease control CompletedThis study looked at whether a dietary supplement (capsules and drink) could reduce hair loss in 240 adults with two common types of hair loss: androgenetic alopecia and chronic telogen effluvium. Participants took the supplement or a placebo daily for 6 months. Researchers measu…
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: NA • Sponsor: Lacer S.A. • Aim: Disease control
Last updated May 26, 2026 09:05 UTC
-
Hair loss breakthrough? new study tests latanoprost acid in women
Symptom relief CompletedThis study tested whether a cosmetic product containing latanoprost acid can improve hair growth in women aged 18-60 with female pattern hair loss or chronic telogen effluvium. 29 women applied one of three strengths of the product daily for 6 months. The main goal was to see if …
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Symptom relief
Last updated May 22, 2026 14:01 UTC